Vivimed Labs has signed definitive agreements and received funds to facilitate additional investment of $7.5 million (follow on of $42.5 million invested in September 2017) by OrbiMed Asia into the company’s subsidiary, Vivimed Labs (Mascarene), the holding entity of the company’s API business.
The proceeds of this additional investment will be utilized to drive business growth and, increase the company’s profitability by organic and inorganic growth opportunities.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
